Clinical Trial News and Research

RSS

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.

10 Feb 2014

pSivida announces financial results for second quarter 2014

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.

10 Feb 2014

Study identifies seven new genetic regions associated with type 2 diabetes

Seven new genetic regions associated with type 2 diabetes have been identified in the largest study to date of the genetic basis of the disease.

9 Feb 2014

Glimmer of hope for Alzheimer’s disease sufferers

Hope may be on its way for sufferers of Alzheimer’s Disease as the Griffith Health Institute seeks participants for new research.

7 Feb 2014

Proprietary supplement improves cognitive processing speed of older adults

Declines in the underlying brain skills needed to think, remember and learn are normal in aging. In fact, this cognitive decline is a fact of life for most older Americans.

7 Feb 2014

Talking therapy may provide effective alternative to medication for people with schizophrenia

Cognitive therapy may provide an effective alternative to antipsychotic medication for patients with schizophrenia, report researchers.

6 Feb 2014

UTHealth unveils country's first Mobile Stroke Unit

The University of Texas Health Science Center at Houston (UTHealth) Medical School, in partnership with Memorial Hermann-Texas Medical Center, has unveiled the country's first Mobile Stroke Unit.

6 Feb 2014

Chemotherapy following radiation therapy improves survival for adults with brain tumor

Adults with low-grade gliomas, a form of brain tumor, who received a chemotherapy regimen following completion of radiation therapy, lived longer than patients who received radiation therapy alone, according to long-term follow-up results from a National Institutes of Health-supported randomized controlled clinical trial.

6 Feb 2014

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.

5 Feb 2014

Study: Ipilimumab with VEGF inhibitors may be potential option for melanoma patients

Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

5 Feb 2014

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces that The Lancet has published the results of its Phase 2 clinical trial of its lead candidate, EMA401, in postherpetic neuralgia (PHN).

5 Feb 2014

Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen

Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announced today that clearance was obtained from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND), Fraunhofer's plant-derived malaria transmission-blocking vaccine (TBV), which targets the Pfs25 antigen, to proceed into the clinic in a Phase 1 safety and immunogenicity study.

5 Feb 2014

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

A new international multi-center study led by researchers from UCSF Benioff Children's Hospital is the first to evaluate whether purified cannabinoid is effective in treating severe forms of childhood epilepsy that do not respond to standard antiepileptic drugs.

5 Feb 2014

New drug treatment effective against chronic pain caused by nerve damage post shingles

A new drug treatment has been found to be effective against chronic pain caused by nerve damage, also known as neuropathic pain, in patients who have had shingles.

5 Feb 2014

Randomized trial shows injecting anesthetic near nerve bundle reduces troublesome hot flashes

Injecting a little anesthetic near a nerve bundle in the neck cut troublesome hot flashes significantly, shows a new randomized, controlled trial published online today in Menopause, the journal of The North American Menopause Society (NAMS).

5 Feb 2014

FDA approves new artificial heart valve device that does not require major open surgery

An artificial heart valve device that does not require major open surgery has been approved by the Food and Drug Administration.

From Medtronic 5 Feb 2014

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.

4 Feb 2014

Pfizer’s palbociclib Phase 2 trial achieves primary endpoint in patients with advanced breast cancer

Pfizer Inc. today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.

4 Feb 2014

BBA supports 510(k) clearance of Kiva VCF Treatment System

Boston Biomedical Associates (BBA) is proud to have supported our client and colleagues at Benvenue Medical, Inc. during The Kiva® System as a Vertebral Augmentation Treatment or KAST trial, and recent 510(k) clearance of the Kiva® VCF Treatment System.

4 Feb 2014

Sanford Hospital starts clinical trial to study dissolving device in patients with CAD

Sanford Heart Hospital has started a clinical trial to study a dissolving device in patients with coronary artery disease. The ABSORB III clinical trial will investigate the safety and effectiveness of the Absorb Bioresorbable Vascular Scaffold (BVS) device, manufactured by global health care company Abbott.

4 Feb 2014

Clinical Trial News and Research

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

pSivida announces financial results for second quarter 2014

Study identifies seven new genetic regions associated with type 2 diabetes

Glimmer of hope for Alzheimer’s disease sufferers

Proprietary supplement improves cognitive processing speed of older adults

Talking therapy may provide effective alternative to medication for people with schizophrenia

UTHealth unveils country's first Mobile Stroke Unit

Chemotherapy following radiation therapy improves survival for adults with brain tumor

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Study: Ipilimumab with VEGF inhibitors may be potential option for melanoma patients

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

New drug treatment effective against chronic pain caused by nerve damage post shingles

Randomized trial shows injecting anesthetic near nerve bundle reduces troublesome hot flashes

FDA approves new artificial heart valve device that does not require major open surgery

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Pfizer’s palbociclib Phase 2 trial achieves primary endpoint in patients with advanced breast cancer

BBA supports 510(k) clearance of Kiva VCF Treatment System

Sanford Hospital starts clinical trial to study dissolving device in patients with CAD

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery